Blood and Lymphatic Cancer : Targets and Therapy
Overview
Blood and Lymphatic Cancer : Targets and Therapy is a scientific journal, published by Dove Medical Press since 2011 in English. The journal's country of origin is New Zealand and its primary focus area is hematology.
Details
Details
Abbr.
Blood Lymphat Cancer
Publisher
Dove Medical Press
Start
2011
End
Continuing
Frequency
Irregular
e-ISSN
1179-9889
Country
New Zealand
Language
English
Specialty
Hematology
Recent Articles
1.
Almodovar Diaz A, Alouch S, Chawla Y, Gonsalves W
Blood Lymphat Cancer
. 2024 Dec;
14:71-87.
PMID: 39664714
Despite recent advancements in treatments, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, multiple myeloma (MM) remains mostly incurable with patients frequently experiencing disease relapses due to therapy resistance. Hence...
2.
Liu D, Tong J, Chen E, Wang L, Xue L, Zhang X, et al.
Blood Lymphat Cancer
. 2024 Aug;
14:63-69.
PMID: 39100972
Background: The aim of the study was to evaluate the efficacy and safety of induction and consolidation with all-trans retinoic acid (ATRA) +arsenic trioxide (ATO) +anthracyclines and maintenance with ATRA...
3.
Zhang Y, Yao X, Zhang Y, Chen Z, Qin Z, Cai Y, et al.
Blood Lymphat Cancer
. 2024 Jul;
14:49-62.
PMID: 38974337
Background: The albumin-to-globulin ratio (AGR) and neutrophil-to-lymphocyte ratio (NLR) have been recently regarded as promising prognostic factors in various malignancies. The present study investigated the prognostic value of combining the...
4.
Mei N, Gong S, Wang L, Wang L, Wang J, Li J, et al.
Blood Lymphat Cancer
. 2024 Jun;
14:31-48.
PMID: 38854627
Background: Multiple myeloma (MM), an incurable plasma cell malignancy. The significance of the relationship between natural killer (NK) cell-related genes and clinical factors in MM remains unclear. Methods: Initially, we...
5.
Zhang J, Zheng Y, Liu H, Liu B
Blood Lymphat Cancer
. 2024 Mar;
14:17-30.
PMID: 38550556
Background: Acute myeloid leukemia (AML) is a hematological malignancy with poor patient prognosis. Cuprotosis is a newly discovered cell death that regulates the proliferation and progression of tumor cells. Long...
6.
Malfona F, Testi A, Chiaretti S, Moleti M
Blood Lymphat Cancer
. 2024 Mar;
14:1-15.
PMID: 38510818
Despite excellent results in frontline therapy, particularly in pediatric age, refractory Burkitt lymphoma still remains a therapeutic challenge, with dismal outcome. The prognosis is very poor, ranging from less than...
7.
Duminuco A, Harrington P, Harrison C, Curto-Garcia N
Blood Lymphat Cancer
. 2023 Dec;
13:77-90.
PMID: 38146420
Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms characterized by impaired quality of life and severe complications. Despite the increasingly in-depth knowledge of this condition, it necessitates a multifaceted...
8.
Alsuhebany N, Pan C, Holovac E, Do B, McBride A
Blood Lymphat Cancer
. 2023 Nov;
13:67-76.
PMID: 38034984
Purpose: The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of zanbrutinib are described. Summary: Mantle cell lymphoma (MCL) is a mature B-cell lymphoma that is typically associated with unfavorable outcomes,...
9.
Wang J, Baidoun F, Tun H, Alhaj Moustafa M
Blood Lymphat Cancer
. 2023 Oct;
13:59-65.
PMID: 37810176
Radioimmunotherapy (RIT) with radio-labeled monoclonal antibodies to CD20 produces a high response rate in patients with low-grade B-cell lymphomas. The use of this modality in patients with chronic lymphocytic leukemia...
10.
Hussain M, Yellapragada S, Al Hadidi S
Blood Lymphat Cancer
. 2023 Sep;
13:33-57.
PMID: 37731771
Multiple myeloma (MM) is a hematologic malignancy characterized by the abnormal clonal proliferation of plasma cells that may result in focal bone lesions, renal failure, anemia, and/or hypercalcemia. Recently, the...